Caitong International Asset Management Co. Ltd Has $128,000 Position in West Pharmaceutical Services, Inc. $WST

Caitong International Asset Management Co. Ltd raised its holdings in West Pharmaceutical Services, Inc. (NYSE:WST) by 72.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 586 shares of the medical instruments supplier’s stock after buying an additional 246 shares during the period. Caitong International Asset Management Co. Ltd’s holdings in West Pharmaceutical Services were worth $128,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. increased its stake in shares of West Pharmaceutical Services by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 9,231,721 shares of the medical instruments supplier’s stock worth $2,066,798,000 after purchasing an additional 244,259 shares during the last quarter. Brown Advisory Inc. increased its stake in shares of West Pharmaceutical Services by 28.1% during the 1st quarter. Brown Advisory Inc. now owns 3,268,478 shares of the medical instruments supplier’s stock worth $731,747,000 after purchasing an additional 716,442 shares during the last quarter. Durable Capital Partners LP increased its stake in shares of West Pharmaceutical Services by 146.8% during the 1st quarter. Durable Capital Partners LP now owns 1,573,119 shares of the medical instruments supplier’s stock worth $352,190,000 after purchasing an additional 935,721 shares during the last quarter. APG Asset Management N.V. increased its stake in shares of West Pharmaceutical Services by 8.7% during the 1st quarter. APG Asset Management N.V. now owns 1,562,139 shares of the medical instruments supplier’s stock worth $323,766,000 after purchasing an additional 124,737 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of West Pharmaceutical Services by 43.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,134,706 shares of the medical instruments supplier’s stock worth $254,038,000 after purchasing an additional 343,997 shares during the last quarter. 93.90% of the stock is currently owned by institutional investors and hedge funds.

West Pharmaceutical Services Stock Performance

NYSE WST opened at $298.13 on Friday. The company has a quick ratio of 2.08, a current ratio of 2.87 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $21.44 billion, a P/E ratio of 44.17, a P/E/G ratio of 5.11 and a beta of 1.07. West Pharmaceutical Services, Inc. has a 12-month low of $187.43 and a 12-month high of $348.90. The firm has a 50-day moving average price of $259.30 and a two-hundred day moving average price of $234.13.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.67 by $0.29. The firm had revenue of $804.60 million during the quarter, compared to the consensus estimate of $788.42 million. West Pharmaceutical Services had a net margin of 16.29% and a return on equity of 18.16%. The business’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.85 EPS. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. Analysts anticipate that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Evercore ISI boosted their price objective on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “outperform” rating in a research note on Thursday. Zacks Research lowered shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 23rd. Redburn Partners set a $311.00 price objective on shares of West Pharmaceutical Services in a research note on Monday, September 15th. Rothschild & Co Redburn assumed coverage on shares of West Pharmaceutical Services in a research note on Monday, September 15th. They set a “buy” rating and a $311.00 price objective on the stock. Finally, Rothschild Redb upgraded shares of West Pharmaceutical Services to a “strong-buy” rating in a research note on Monday, September 15th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, West Pharmaceutical Services currently has a consensus rating of “Moderate Buy” and an average target price of $343.56.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.